Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that a specific mutation in the mouse RXRalpha gene significantly impacts immune responses and causes hair loss and skin cysts.

This report describes two cases where patients developed alopecia while undergoing treatment for psoriasis with IL-17 inhibitors, suggesting an unexpected paradoxical reaction.

This study found that Th17 lymphocytes may play a more crucial role than cytotoxic T cells in the development of alopecia areata due to their infiltration around the hair bulb/bulge, which exacerbates hair loss as histopathological grade worsens.

This review discusses various potential treatments for alopecia areata, highlighting the promise of Janus kinase inhibitors but reports no new clinical results.

This review discusses the complex role of immune disturbances and the JAK-STAT pathway in alopecia areata, noting the success of JAK inhibitors in treatment, while highlighting ongoing debates and challenges in targeting other pathways like IL-17 and TNF-α.

This study found that genetic variants linked to hypothyroidism significantly increased the risk of developing alopecia areata, suggesting a causative connection between the two conditions.

In this study, researchers used spatial transcriptome profiling to identify immune disturbances in the peri-infundibular region of androgenetic alopecia patients’ hair follicles, finding increased CD4+ T cells with a bias toward Th2 immune responses compared to controls.

Small molecule DMF improves psoriasis and multiple sclerosis, adult skin cells can be made to grow new hair, certain skin cells initiate hair growth, IL-17C controls gut health and can cause skin inflammation, and skin cells produce IL-17 that can lead to psoriasis.

Dithranol reduces inflammation in alopecia areata by lowering certain immune responses.

This study found that mRNA booster vaccinations for SARS-CoV-2 increased protective antibodies without worsening autoimmune disease activity in patients with pemphigus and bullous pemphigoid.

The document concludes that doctors should recognize congenital triangular alopecia to avoid unnecessary treatments, as it does not respond to steroids like alopecia areata does.

This study found that reduced expression of CD200R1 on monocyte-derived macrophages in rheumatoid arthritis patients was significantly associated with higher disease severity and an imbalance in Th17/Treg cells.

This study found that activating Wnt/beta-catenin signaling in hair follicles is sufficient to induce adipocyte generation in the dermis, affecting both hair follicle stem cell activation and adipocyte differentiation.

This review discusses immune pathways involved in alopecia areata and explores emerging, more targeted therapeutic strategies, noting their potential for better safety and effectiveness compared to traditional immune suppressants.

This study conducted a meta-analysis of gene expression data from alopecia areata patients, identifying 5109 differentially expressed genes and highlighting enriched pathways like JAK-STAT signaling, providing insights into the disease's pathogenesis and potential treatment targets.

This study found that both Th1 and Th2 immune responses, along with IL-23 and IL-32 cytokine pathways, are active in alopecia areata lesions, and corticosteroid injections significantly altered these immune markers.

In this study, researchers observed that follicular damage and stem cell loss in frontal fibrosing alopecia may be mediated by immune attacks at the bulge region, suggesting potential for JAK/STAT-targeting treatments to prevent progression.

This study suggests that targeting specific immune pathways, such as IL-12/23 and Th2 cytokines, may offer new treatment options for alopecia areata, a T-cell-mediated disease without current mechanism-specific therapies.

This study found that oral JAK3 and TYK2/JAK1 inhibitors improved clinical outcomes in alopecia areata patients by reducing immune responses and enhancing hair keratin expression, with stronger effects in those with shorter disease duration.

This review discusses the complexities of hidradenitis suppurativa pathogenesis, highlighting issues with Notch signaling, immune dysregulation, and the role of keratinocytes and ECM, but reports no new clinical results.

This review discusses the shared biological mechanisms between allergy and autoimmunity, emphasizing pruritus as a central symptom in psychophysiological dermatoses, and reports no new clinical results.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

This study found that epidermal growth factor receptor inhibitors used in cancer treatment induce a distinct inflammatory response in hair follicles, marked by immune privilege collapse and upregulation of inflammatory pathways.

In this study, researchers observed that alopecia areata patients showed higher Th1 and Th2 responses against specific melanogenesis-related protein epitopes, suggesting a role in disease activity and potential targets for diagnostics and therapies.

This review discusses immunological abnormalities in PCOS, focusing on inflammation and autoantibody production, and reports no new results; it suggests exploring new therapeutic drug targets.

This study found that canine pemphigus foliaceus skin lesions exhibit a distinct immune signature, with upregulated pro-inflammatory and Th17-related genes, showing similarities to human pemphigus. Further research using advanced sequencing is needed to better understand the disease's pathogenesis.

This study identified shared gene expression changes and immune cell infiltration patterns that may contribute to hair loss in alopecia areata and cutaneous lupus erythematosus, but also highlighted factors that might preserve hair in psoriasis patients.

This study found that individuals with AA have a higher incidence of atopic and autoimmune conditions, suggesting both Th1 and Th2 immune responses may play a role in its development.

This research discusses the complex immune pathogenesis of alopecia areata and highlights the success of Jak inhibitors and IL-4Rα antagonists, while IL-17A and PDE4 inhibitors showed limited efficacy; controlled trials are advocated to better understand cytokine involvement.

This study found that in patients with alopecia areata and atopic dermatitis, 61.5% showed improvement with dupilumab treatment, but 38.5% experienced worsened or new-onset alopecia areata, with higher baseline IgE levels linked to better responses.